Community Practice Connections™: 20th Annual International Congress on the Future of Breast Cancer®

Release Date: September 30, 2021
Expiration Date: September 30, 2022

Activity Overview

The management of breast cancer is evolving rapidly with new treatment options and new indications for approved agents emerging at a record pace. Novel agents and improved regimens      coupled with more in-depth molecular and phenotypic subtyping are driving the future of breast cancer therapy. Current standards of care require the use of biomarkers and molecular assays to characterize each patient’s tumor as well as assessment of the benefit-risk ratio for individual therapeutic options in the context of patient comorbidities and preferences.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 20th Annual International Congress on the Future of Breast Cancer^®, held in July 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with breast cancer and putting recent clinical trial data into context. The program is designed to inform those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Eisai Inc., Exact Sciences Corporation, Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Puma Biotechnology, Inc., Sanofi Genzyme and Seagen Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Target Audience

The target audience for this activity is medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate results from genomic and/or molecular biomarker assays to characterize tumor subtype, assess risk, and individualize treatment selection for patients with breast cancer
• Incorporate evidence from recent clinical trials of systemic agents for the treatment of early-stage and metastatic breast cancer into personalized treatment plans to ensure optimal patient outcomes
• Assess emerging data from clinical trials of novel investigational agents for the treatment of breast cancer      and how these data may impact treatment algorithms
• Implement multidisciplinary team-based strategies for recognizing and managing treatment-related adverse events for patients with breast cancer in order to reduce risk of harm while maintaining efficacy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities

Faculty

Sara Hurvitz, MD, FACP
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monic
UCLA Outpatient Hematology/Oncology Practice
Assistant Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA Santa Monica, CA

Disclosures: Grant research support: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer Healthcare, Daiichi Sankyo, Genentech/Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, Eli Lilly and Company, MacroGenics, Novartis Pharmaceuticals Corporation , Biosplice Therapeutics (formerly Samumed), Sanofi, Seagen (formerly Seattle Genetics), Dignitana, Zymeworks, Phoenix Molecular Designs; Shareholder: NKMaX (spouse): ROMTech, IDEAL IMPLANT; Other: Travel: Eli Lilly and Company

William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology
Department of Medicine
Chief, Division of Hematology and Oncology in the Department of Medicine Deputy Director, Clinical Network
Director, Maggie Daley Center for Women’s Cancer Care
Robert H. Lurie Comprehensive Cancer Center Northwestern University
Chicago, IL

Disclosures: Consultant: AstraZeneca, MacroGenics, Seagen, Gilead Sciences, Novartis Pharmaceuticals Corporation.

Joyce O’Shaughnessy, MD
Celebrating Woman Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology
Dallas, TX

Disclosures: Consultant: Novartis Pharmaceuticals Corporation, AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck & Co, Pfizer, Seattle Genetics

Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant research support: Novartis Pharmaceuticals Corporation, Polyphor; Consultant: Novartis Pharmaceuticals Corporation, Pfizer, AstraZeneca, GlaxoSmithKline, Immunomedics, Exact Sciences/Genomic Health, OncoPep

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.